Attovia Therapeutics
ATTO
16.04
-0.38
-2.31%
Attovia Therapeutics
US · ATTO
#3464 by market cap
Listed 2026
16.04
-0.38
-2.31%
Live - 5344 symbols - heartbeat 426s ago
· 2026-10-08 10:00
Pre-market
16.97
+3.35%
After-hours
16.42
0.00%
- Market cap
- 732.25M
- P/E (TTM)i
- -10.40
- P/Bi
- -5.03
- EPSi
- -1.42
- Div yieldi
- 0.00%
- 52W posi
- 1%
Reader sentiment
Are you bullish or bearish on ATTO?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is 0.39, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Margins
- Operating margin
- -4,974.74%
- Net margin
- -4,510.96%
Key ratios & quality
- Altman Z-Scorei
- 0.39
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.76B | 1.92B | 1.82B | 1.71B | 1.41B | 1.45B | 0 | 1.35M |
| Gross profit | 1.69B | 1.85B | 1.75B | 1.64B | 1.34B | 1.34B | -- | -- |
| Selling & admin expenses | 1.31B | 1.53B | 1.48B | 1.40B | 1.12B | 1.16B | 7.69M | 14.36M |
| Research & development | -- | -- | -- | -- | -- | -- | 33.86M | 54.15M |
| Operating profit | 74.81M | 130.38M | 115.73M | 35.74M | 41.52M | 15.28M | -41.55M | -67.16M |
| Pretax profit | 8.56M | -1.04M | 33.90M | -44.48M | -42.10M | -88.49M | -39.80M | -60.63M |
| Tax | 5.21M | 12.53M | 13.41M | 36.22M | 4.78M | 4.46M | -- | -- |
| Net profit | 151.00K | -13.57M | 20.49M | -80.69M | -46.88M | -92.95M | -39.80M | -60.63M |
| Basic EPS | 0 | -1 | 1 | -6 | -3 | -7 | -2 | -2 |
| Diluted EPS | 0.05 | -1.16 | 1.25 | -5.63 | -3.33 | -6.61 | -1.75 | -2.37 |
| Line item | 2022-06 | 2022-09 | 2025-03 | 2025-06 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 363.80M | 346.80M | -- | 0 | -- | 450.00K |
| Gross profit | 333.70M | 311.48M | -- | -- | -- | -- |
| Selling & admin expenses | 283.60M | 255.57M | 4.25M | 3.03M | 3.21M | 3.31M |
| Research & development | -- | -- | 11.86M | 13.59M | 16.75M | 18.95M |
| Operating profit | -3.10M | 7.93M | -16.10M | -16.62M | -19.96M | -21.80M |
| Pretax profit | -15.80M | 14.99M | -15.15M | -14.44M | -18.66M | -20.69M |
| Tax | -3.70M | 13.50M | -- | -- | -- | -- |
| Net profit | -12.10M | 1.49M | -15.15M | -14.44M | -18.66M | -20.69M |
| Basic EPS | -1 | 0 | -1 | -1 | -1 | 0 |
| Diluted EPS | -0.83 | 0.10 | -0.60 | -0.56 | -0.73 | -0.48 |
Balance sheet
| Line item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 574.67M | 566.18M | 496.47M | 538.77M | 571.80M | 501.64M | 72.48M | 156.30M |
| Cash & ST investments | 195.18M | 142.77M | 134.15M | 125.72M | 210.15M | 129.57M | 69.32M | 152.27M |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 1.38B | 1.33B | 1.21B | 1.30B | 1.18B | 1.11B | 76.72M | 165.89M |
| Total current liabilities | 348.61M | 369.60M | 344.39M | 378.60M | 404.79M | 437.11M | 7.72M | 11.01M |
| Short-term debt | 54.58M | 46.56M | 51.34M | 87.12M | 133.19M | 119.02M | -- | 1.92M |
| Long-term debt | 478.93M | 433.49M | 406.06M | 490.76M | 495.12M | 488.75M | -- | -- |
| Total liabilities | 947,415,000.00 | 952,466,000.00 | 873,261,000.00 | 1,097,591,000.00 | 1,056,447,000.00 | 1,120,651,000.00 | 123,541,000.00 | 273,329,000.00 |
| Total equity | 430.20M | 377.84M | 340.09M | 207.02M | 119.68M | -12.88M | -46.83M | -107.44M |
| Retained earnings | -53.60M | -94.54M | -16.33M | -127.07M | -178.99M | -273.25M | -50.38M | -111.01M |
| Line item | 2022-06 | 2022-09 | 2025-03 | 2025-06 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 453.83M | 458.61M | -- | -- | 136.64M | 118.40M |
| Cash & ST investments | 103.87M | 67.76M | -- | -- | 132.62M | 115.13M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 1.03B | 992.46M | -- | -- | 146.09M | 128.35M |
| Total current liabilities | 445.44M | 485.24M | -- | -- | 9.80M | 12.62M |
| Short-term debt | 154.39M | 138.03M | -- | -- | 1.98M | 2.04M |
| Long-term debt | 488.91M | 489.58M | -- | -- | -- | -- |
| Total liabilities | 1,161,896,000.00 | 1,156,540,000.00 | -- | -- | 271,601,000.00 | 273,807,000.00 |
| Total equity | -130.93M | -164.08M | -- | -- | -125.52M | -145.46M |
| Retained earnings | -356.47M | -354.97M | -- | -- | -129.67M | -150.35M |
Cash flow
| Line item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 141.95M | 114.45M | 81.19M | 46.52M | 126.99M | 42.30M | -35.04M | -59.20M |
| Depreciation & amortization | 97.36M | 104.42M | 95.25M | 140.78M | 120.92M | 133.23M | 313.00K | 804.00K |
| Free cash flow | 72.10M | 37.59M | 40.02M | 6.46M | 88.81M | -5.81M | -36.81M | -61.51M |
| Dividends paid | 0 | -24.35M | -2.32M | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 0 | -8.18M | -11.14M | -1.33M | -878.00K | 310.00K | 194.00K |
| Ending cash balance | 194.04M | 141.76M | 133.53M | 124.71M | 208.99M | 128.82M | 31.24M | 40.60M |
| Line item | 2022-06 | 2022-09 | 2025-03 | 2025-06 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 27.50M | -1.35M | -14.13M | -12.57M | -18.14M | -16.79M |
| Depreciation & amortization | 31.40M | 30.52M | 143.00K | 207.00K | 242.00K | 246.00K |
| Free cash flow | 18.90M | -12.41M | -15.92M | -12.66M | -18.43M | -16.86M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 0 | 45.00K | 98.00K | 11.00K | 31.00K |
| Ending cash balance | 102.90M | 66.31M | 129.71M | 43.05M | 43.70M | 33.23M |
Returns & efficiency
| Line item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 0.02 | -3.40 | 5.30 | -30.19 | -28.70 | -174.06 | -- | -- |
| ROA %i | 0.00 | -1.00 | 1.46 | -6.46 | -3.78 | -8.14 | -58.72 | -50.20 |
| ROIC %i | 4.63 | 3.61 | 4.22 | -5.77 | -1.22 | -5.48 | -- | -- |
| 5-year avg ROE %i | -- | -- | -2.59 | -3.54 | -11.56 | -46.37 | -- | -- |
| EBIT margin %i | 4.76 | 4.01 | 4.37 | 1.38 | 2.00 | 0.23 | -- | -4,974.74 |
| FCF / sales %i | 4.10 | 1.96 | 2.20 | 0.38 | 6.29 | -- | -- | -- |
| Current ratioi | 1.65 | 1.53 | 1.44 | 1.42 | 1.41 | 1.15 | 9.39 | 14.20 |
| Quick ratioi | 1.64 | 1.51 | 1.39 | 1.39 | 1.38 | 1.12 | 8.98 | 13.83 |
| Debt / assetsi | 38.83 | 36.55 | 37.89 | 55.24 | 61.88 | 64.84 | 0.00 | 3.17 |
| LT debt / equityi | 111.47 | 119.37 | 123.19 | 306.01 | 496.87 | -- | -- | -- |
| Interest coveragei | 1.11 | 0.99 | 1.74 | 0.35 | 0.40 | 0.04 | -- | -- |
| Revenue CAGR (3Y) %i | -9.12 | -5.52 | -2.30 | -0.96 | -9.75 | -7.28 | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -27.75 | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | 29.17 | -- | -55.26 | 33.19 | -- | -- | -- |
| Line item | 2022-06 | 2022-09 | 2025-03 | 2025-06 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -- | -- | -- | -- |
| ROA %i | -12.85 | -12.15 | -- | -- | -43.90 | -54.84 |
| ROIC %i | -- | -- | -- | -- | -- | -- |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -4.98 | -3.98 | -- | -- | -5,260.00 | -4,232.94 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 1.02 | 0.95 | -- | -- | 13.94 | 9.39 |
| Quick ratioi | 1.00 | 0.93 | -- | -- | 13.53 | 9.13 |
| Debt / assetsi | 71.53 | 72.10 | -- | -- | 3.29 | 3.37 |
| LT debt / equityi | -- | -- | -- | -- | -- | -- |
| Interest coveragei | -0.84 | -0.70 | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Research and development of therapeutic products in the fields of immune-mediated diseases100.00%
Quote time 2026-10-08 10:00:18 · For reference only, not investment advice and not tailored to your situation.